阿托伐他汀对糖尿病肾病患者血同型半胱氨酸及纤维蛋白原水平影响.docVIP

阿托伐他汀对糖尿病肾病患者血同型半胱氨酸及纤维蛋白原水平影响 　　【摘要】 目的：探讨阿托伐他汀对糖尿病肾病患者血同型半胱氨酸、纤维蛋白原水平的影响。方法：选取50例确诊为糖尿病肾病的患者，根据血脂水平分为A组（血脂正常组）和B组（血脂升高组）；A组随机数字表法分为对照组（A1组）和治疗组（A2组）。A1组、A2组及B组均给予糖尿病基础治疗。A2组和B组在糖尿病基础治疗上增加口服阿托伐他汀。比较各组患者治疗前后的血同型半胱氨酸、纤维蛋白原水平等指标的改变。结果：A组治疗前血同型半胱氨酸（Hcy）及纤维蛋白原均低于B组（P0.05），A1、A2组患者治疗前Hcy及纤维蛋白原无明显差异，A2组治疗后Hcy水平及纤维蛋白原均低于A1组（P0.05），B组治疗后Hcy水平及纤维蛋白原均显著降低（P0.05）。结论：阿托伐他汀能降低糖尿病肾病患者血同型半胱氨酸、纤维蛋白原水平，发挥降血脂以外的血管保护作用，以延缓糖尿病肾病进展。 　　【关键词】 阿托伐他汀； 糖尿病肾病； 同型半胱氨酸； 纤维蛋白原 　　【Abstract】 Objective：To investigate the effect of atorvastatin on blood homocysteine and fibrinogen level in patients with diabetic nephropathy.Method：50 cases who were diagnosed with diabetic nephropathy were divided into group A （normal lipid group） and group B （elevated blood lipids group） according to their lipid levels.The A group were randomly divided into control group （A1 group） and treatment group （A2 group）.Group A1，A2 and group B were given basic treatment of diabetes.A2 group and B group were given oral atorvastatin on the basis treatment of diabetes.Changes in blood homocysteine，fibrinogen level and other indicators before and after treatment were compared between the two groups.Result：Before treatment，blood Hcy and fibrinogen level of the group A were lower than those of the B group（P0.05）.There were no differences between A1 and A2 about the blood Hcy and fibrinogen level before treatment.After treatment，blood Hcy level and fibrinogen level of group A2 were lower than those of group A1，Hcy level and fibrinogen level of group B were significantly lower than before treatment（P0.05）.Conclusion：Atorvastatin can reduce blood homocysteine and fibrinogen level in diabetic nephropathy，it can not only lower blood lipid but also protect vascular，so as to delay the progression of diabetic nephropathy. 　　【Key words】 Atorvastatin； Diabetic nephropathy； Homocysteine； Fibrinogen 　　糖尿病肾病（Diabetic nephropathy，DN）是糖尿病（diabetes mellitus，DM）的重要并发症及主要致死原因之一[1]。是糖尿病病人最重要的合并症之一。我国的发病率亦呈上升趋势，目前已成为终末期肾脏病的第二位原因，仅次于各种肾小球肾炎。由于其